GARFIELD-AF: A Worldwide Prospective Registry of Patients With Atrial Fibrillation at Risk of Stroke

Abstract

The Global Anticoagulant Registry in the Field-Atrial Fibrillation (GARFIELD-AF) examined real-world practice in a total of 57,149 (5069 retrospective, 52,080 prospective) patients with newly diagnosed AF at risk of stroke/systemic embolism, enrolled at over 1000 centers in 35 countries. It aimed to capture data on AF burden, patients’ clinical profile, patterns of clinical practice and antithrombotic management, focusing on stroke/systemic embolism prevention, uptake of new oral anticoagulants, impact on death and bleeding. GARFIELD-AF set new standards for quality of data collection and analysis. A total of 36 peer-reviewed articles were already published and 73 abstracts presented at international congresses, covering treatment strategies, geographical variations in baseline risk and therapies, adverse outcomes and common comorbidities such as heart failure. A risk prediction tool as well as innovative observational studies and artificial intelligence methodologies are currently being developed by GARFIELD-AF researchers.

Clinical Trial Registration: NCT01090362 (ClinicalTrials.gov).

Infographic

Infographic: A PDF version of this infographic is available as supplemental material.

Keywords:

• artificial intelligence (AI)
• atrial fibrillation (AF)
• GARFIELD-AF
• nonvitamin K oral anticoagulant (NOAC)
• observational study

Supplementary data

Acknowledgments

The authors thank the physicians, nurses and patients involved in GARFIELD-AF as well as statisticians and programmers at Thrombosis Research Institute (TRI), London, UK. A Kahney of TRI provided editorial support.

Financial & competing interests disclosure

The GARFIELD-AF registry is sponsored by TRI and supported by an unrestricted research grant from Bayer AG, Berlin, Germany. The sponsor had no involvement in the collection, analysis or interpretation of the data.

J-P Bassand reports personal fees from Thrombosis Research Institute, during the conduct of the study. D Atar has received personal fees from Bayer Healthcare, BMS/Pfizer, Boehringer-Ingelheim and MSD. AJ Camm has received institutional grants and personal fees from Bayer, Boehringer Ingelheim, Pfizer/BMS and Daiichi Sankyo. F Cools reports personal fees from Bayer, personal fees from BMS, personal fees from Boehringer-Ingelheim, outside the submitted work. DA Fitzmaurice reports personal fees from Bayer outside the submitted work. KAA Fox has received grants and personal fees from Bayer/Janssen and AstraZeneca and personal fees from Sanofi/Regeneron and Verseon outside the submitted work. S Goto has received personal fees from the Thrombosis Research Institute, Harvard University, the American Heart Association and grants from the Vehicle Racing Commemorative Foundation, Nikitina Foundation for Advancement of Measuring Technologies in Biomedical Engineering, Bristol-Myers Squibb, Sanofi, Ono and Pfizer. S Haas has received personal fees from Aspen, Bayer Healthcare, BMS/Pfizer, Daiichi-Sankyo, Portola and Sanofi. W Hacke reports that he was on the steering committee of RROCKET AF and was reimbursed for travel and time by Bayer until 2013. He is also member of the steering committee of GARFIELD AF and received travel reimbursement. Y Koretsune reports research grant from Daiichi Sankyo and Boehringer Ingelheim. Paid lecture: Daiichi Sankyo, Boehringer Ingelheim, Bayer, Bristol Meyers and Pfizer. J-YL Heuzey reports fees (modests) for participating to advisory boards: Bayer, Boehringer Ingelheim, BMS/Pfizer and Daiichi-Sankyo. JPS Sawhney reports personal fee from Pfizer, Astra Zeneca, Novartis, Sanofi and BMS. S Oh has received consultant/advisory board payments for Bayer Pharma AG, Bristol-Myers Squibb Korea, Boehringer-Ingelheim Korea, Pfizer Korea, Sanofi-Aventis and St Jude Medical, outside the submitted work. J Stępińska has received grants from Bayer; personal fees from Bayer, Boehringer Ingelheim, BMS/Pfizer, Novartis and Servier; has served as an expert witness for Boehringer Ingelheim; has served as a consultant or on an advisory board for Amgen, Boehringer Ingelheim, Novartis and Sanofi. FWA Verheugt has received grants from Bayer Healthcare; personal fees from Bayer Healthcare, BMS/Pfizer, Daiichi-Sankyo and Boehringer-Ingelheim. AK Kakkar has received research support from Bayer AG; personal fees from Bayer AG, Janssen Pharma, Sanofi, SA Pfizer and Verseon. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained verbal and written informed consent from the patient/patients for the inclusion of their medical and treatment history within this article.

Infographic disclosure

An infographic accompanies this paper at the end of the references section. To download the infographic that accompanies this paper, please visit the journal website at: www.tandfonline.com/doi/full/10.2217/fca-2020-0014